MX2015000337A - Formulaciones de etanercept que exhiben reduccion notable en particulas subvisibles. - Google Patents

Formulaciones de etanercept que exhiben reduccion notable en particulas subvisibles.

Info

Publication number
MX2015000337A
MX2015000337A MX2015000337A MX2015000337A MX2015000337A MX 2015000337 A MX2015000337 A MX 2015000337A MX 2015000337 A MX2015000337 A MX 2015000337A MX 2015000337 A MX2015000337 A MX 2015000337A MX 2015000337 A MX2015000337 A MX 2015000337A
Authority
MX
Mexico
Prior art keywords
sub
visible particles
marked reduction
etanercept formulations
formulations exhibiting
Prior art date
Application number
MX2015000337A
Other languages
English (en)
Inventor
Mark Manning
Brian Murphy
Douglas Farrar
Alan Herman
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49916504&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015000337(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of MX2015000337A publication Critical patent/MX2015000337A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención proporciona composiciones de etanercept farmacéuticas acuosas estabilizadas apropiadas para el almacenamiento a largo plazo de etanercept, con reducción substancial en partículas subvisibles, y métodos de fabricación de estas composiciones, métodos de administración, y artículos de fabricación.
MX2015000337A 2012-07-09 2013-07-09 Formulaciones de etanercept que exhiben reduccion notable en particulas subvisibles. MX2015000337A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261669480P 2012-07-09 2012-07-09
US201361806235P 2013-03-28 2013-03-28
PCT/US2013/049778 WO2014011672A1 (en) 2012-07-09 2013-07-09 Etanercept formulations exhibiting marked reduction in sub-visible particles

Publications (1)

Publication Number Publication Date
MX2015000337A true MX2015000337A (es) 2015-09-25

Family

ID=49916504

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000337A MX2015000337A (es) 2012-07-09 2013-07-09 Formulaciones de etanercept que exhiben reduccion notable en particulas subvisibles.

Country Status (19)

Country Link
US (3) US9662396B2 (es)
EP (2) EP2869817A4 (es)
JP (2) JP6271536B2 (es)
KR (1) KR20150030704A (es)
CN (1) CN104661651A (es)
AU (1) AU2013290289B2 (es)
BR (2) BR112015000203A2 (es)
CA (1) CA2878508A1 (es)
CL (1) CL2015000051A1 (es)
DO (1) DOP2015000006A (es)
EA (1) EA029193B1 (es)
EC (1) ECSP15004752A (es)
HK (2) HK1213174A1 (es)
IL (1) IL236527A0 (es)
IN (1) IN2015KN00005A (es)
MX (1) MX2015000337A (es)
PE (1) PE20150762A1 (es)
SG (1) SG11201500138VA (es)
WO (2) WO2014011672A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080311078A1 (en) 2005-06-14 2008-12-18 Gokarn Yatin R Self-Buffering Protein Formulations
PE20150996A1 (es) * 2012-09-11 2015-08-01 Coherus Biosciences Inc Etanercept correctamente plegado de alta pureza y excelente rendimiento
JP2016518386A (ja) * 2013-05-02 2016-06-23 マブキシェンス エス．アー． ＴＮＦＲ：Ｆｃ融合ポリペプチドの代替配合物
LT3122358T (lt) 2014-03-26 2021-04-12 Astex Therapeutics Ltd. Egfr ir cmet inhibitorių deriniai, skirti vėžio gydymui
US20180200325A1 (en) * 2014-11-18 2018-07-19 Shionogi & Co., Ltd. Stabilized peptide composition
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
MX2015010517A (es) * 2015-08-13 2017-02-13 Landsteiner Scient S A De C V Composicion de estabilidad mejorada de etanercept.
JP6877196B2 (ja) * 2016-03-14 2021-05-26 参天製薬株式会社 メグルミン又はその塩からなる防腐剤
MX2019004580A (es) 2016-10-21 2019-08-12 Amgen Inc Formulaciones farmaceuticas y metodos para prepararlas.
CN116327963A (zh) * 2016-11-21 2023-06-27 济世-伊沃泰克生物制品有限公司 一种眼科制剂及其用途
MX2017013995A (es) * 2017-10-31 2019-05-01 Probiomed S A De C V Formulacion farmaceutica estable de una proteina de fusion.
US20200323958A1 (en) * 2017-11-13 2020-10-15 Amgen Inc. Methods for producing protein products
CA3097059A1 (en) * 2018-04-16 2019-10-24 Merck Patent Gmbh Method for stabilizing protein comprising formulations by using a meglumine salt
SG11202010430QA (en) * 2018-04-24 2020-11-27 Amgen Inc Method for making injectable pharmaceutical compositions
CA3042126A1 (en) 2018-05-03 2019-11-03 Michael A. Portman Methods of treating kawasaki disease
TR201808283A2 (tr) * 2018-06-11 2018-07-23 Centurion Ilac San Ve Tic A S Sulu farmasöti̇k etenersept bi̇leşi̇mi̇
GB201911461D0 (en) * 2019-08-09 2019-09-25 Arecor Ltd Novel composition
JP2022553751A (ja) * 2019-10-28 2022-12-26 アストラゼネカ・アクチエボラーグ ロイシン及びトリロイシンを含む乾燥粉末製剤
CA3208945A1 (en) 2021-02-17 2022-08-25 Arecor Limited Aqueous composition of an engineered protein construct comprising an fc domain

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
EP1171148A2 (en) 1999-04-19 2002-01-16 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders
MXPA02007683A (es) 2000-02-10 2002-12-13 American Home Prod Metodo para tratar o inhibir la lesion celular o muerte celular.
DK1441589T3 (da) * 2001-11-08 2012-08-06 Abbott Biotherapeutics Corp Stabil, flydende, farmaceutisk sammensætning af IgG-antistoffer
SI1946776T1 (sl) 2002-02-27 2017-07-31 Immunex Corporation Stabiliziran tnfr-fc sestavek, ki obsega arginin
ATE394123T1 (de) 2003-02-28 2008-05-15 Ares Trading Sa Flüssige formulierungen des tumornekrosefraktor- bindungsproteins tbp-1
WO2004082715A1 (ja) * 2003-03-20 2004-09-30 Eisai Co., Ltd. 炎症性腸疾患治療剤としての併用医薬
AU2004262014B2 (en) 2003-08-01 2010-06-17 Amgen Inc. Crystalline tumor necrosis factor receptor 2 polypeptides
RS20110578A3 (en) * 2003-10-14 2016-02-29 F. Hoffmann-La Roche Ltd MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS
JP5554466B2 (ja) 2004-03-01 2014-07-23 味の素株式会社 抗ヒトＴＮＦ−α抗体活性低下抑制剤
US8206981B2 (en) 2004-03-05 2012-06-26 Dsm Ip Assets B.V. Process for cell culturing by continuous perfusion and alternating tangential flow
US20060008415A1 (en) * 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
AU2006256041B2 (en) 2005-06-10 2012-03-29 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
CA2634547C (en) * 2005-12-20 2016-10-11 Bristol-Myers Squibb Company Stable ctla4 formulation for subcutaneous administration
EP1962907A2 (en) 2005-12-21 2008-09-03 Wyeth a Corporation of the State of Delaware Protein formulations with reduced viscosity and uses thereof
BRPI0709598A8 (pt) 2006-03-17 2019-01-08 Biogen Idec Inc composições de polipeptídeos estabilizados
AU2007240732B2 (en) 2006-04-21 2013-07-04 Amgen, Inc. Buffering agents for biopharmaceutical formulations
TW200831129A (en) 2006-10-06 2008-08-01 Amgen Inc Stable formulations
AU2007309616B2 (en) * 2006-10-20 2011-10-06 Amgen Inc. Stable polypeptide formulations
ES2541546T3 (es) 2006-11-03 2015-07-21 Wyeth Llc Sustancias que inhiben la glucólisis en cultivo celular
MX2009006594A (es) 2006-12-21 2009-08-12 Amgen Inc Formulaciones de ph regulado y estables que contienen polipeptidos.
MX2009009240A (es) 2007-03-02 2009-09-08 Wyeth Corp Uso de cobre y glutamato en el cultivo celular para la produccion de polipeptidos.
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
SI2170390T1 (sl) 2007-06-14 2019-02-28 Biogen Ma Inc. Oblike protitelesa natalizumab
CN101969971A (zh) * 2007-11-30 2011-02-09 雅培制药有限公司 蛋白制剂及其制备方法
AU2009210741A1 (en) * 2008-02-07 2009-08-13 Amgen Inc. Stabilized protein compositions
AU2009222115A1 (en) 2008-02-29 2009-09-11 Biogen Idec Ma Inc. Purified immunoglobulin fusion proteins and methods of their purification
PL2331090T3 (pl) * 2008-09-19 2018-05-30 Pfizer Inc. Stabilny ciekły preparat przeciwciała
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
KR20200111282A (ko) 2009-08-11 2020-09-28 제넨테크, 인크. 글루타민-비함유 세포 배양 배지에서의 단백질의 생성
EP2490780A4 (en) 2009-10-20 2014-04-09 Merck Sharp & Dohme USE OF MIXED MODE CHROMATOGRAPHY FOR CAPTURE AND PURIFICATION OF BASIC ANTIBODY PRODUCTS
WO2011079308A2 (en) 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
PL2563904T3 (pl) 2010-04-26 2015-06-30 Novartis Ag Udoskonalona pożywka do hodowli komórkowej
WO2011141926A2 (en) * 2010-05-10 2011-11-17 Intas Biopharmaceuticals Limited Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
EP2598167B1 (en) * 2010-07-30 2015-04-01 Arecor Limited Stabilized aqueous antibody compositions
CA2807607A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
JP2012049074A (ja) 2010-08-30 2012-03-08 Makita Corp 電動工具のバッテリパック
CN103097516B (zh) 2010-08-31 2015-09-09 菲仕兰品牌公司 真核细胞培养基
AU2012244764B2 (en) * 2011-04-20 2016-10-13 Sandoz Ag Stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
CA2838695C (en) 2011-07-01 2017-02-14 Amgen Inc. Mammalian cell culture
DK2726090T3 (da) * 2011-07-01 2020-01-20 Biogen Ma Inc Argininfri tnfr: fc-fusionspolypeptidsammensætninger
KR20140083037A (ko) * 2011-10-18 2014-07-03 코히러스 바이오사이언시즈, 인코포레이티드 아미노산으로 안정화된 에타너셉트 제형

Also Published As

Publication number Publication date
BR112015000229A2 (pt) 2017-06-27
US10822429B2 (en) 2020-11-03
PE20150762A1 (es) 2015-06-20
DOP2015000006A (es) 2015-05-31
EP2869817A1 (en) 2015-05-13
BR112015000203A2 (pt) 2017-06-27
IN2015KN00005A (es) 2015-07-31
HK1209343A1 (en) 2016-04-01
EP2869816A4 (en) 2016-04-20
US20150125532A1 (en) 2015-05-07
ECSP15004752A (es) 2015-12-31
US9662396B2 (en) 2017-05-30
US20150196645A1 (en) 2015-07-16
EA201590161A1 (ru) 2015-07-30
EA029193B1 (ru) 2018-02-28
HK1213174A1 (zh) 2016-06-30
AU2013290289A1 (en) 2015-01-29
WO2014011672A1 (en) 2014-01-16
EP2869817A4 (en) 2016-04-06
JP2015525762A (ja) 2015-09-07
IL236527A0 (en) 2015-02-26
CL2015000051A1 (es) 2015-07-31
CN104661651A (zh) 2015-05-27
CA2878508A1 (en) 2014-01-16
JP6271536B2 (ja) 2018-01-31
AU2013290289B2 (en) 2018-03-29
US20210007991A1 (en) 2021-01-14
JP2015525763A (ja) 2015-09-07
KR20150030704A (ko) 2015-03-20
EP2869816A1 (en) 2015-05-13
WO2014011629A1 (en) 2014-01-16
SG11201500138VA (en) 2015-03-30

Similar Documents

Publication Publication Date Title
MX2015000337A (es) Formulaciones de etanercept que exhiben reduccion notable en particulas subvisibles.
MX2019009176A (es) Formulaciones de etanercept estabilizadas con iones metalicos.
WO2014039903A3 (en) Stable aqueous formulations of adalimumab
MX2023008180A (es) Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.
MY179756A (en) Stabilized efinaconazole formulations
PH12016501122A1 (en) Delayed release compositions of linaclotide
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
WO2015048689A8 (en) Inhibitors of bruton's tyrosine kinase
MX2016008448A (es) Conjugados de var2csa-farmaco.
NZ709958A (en) Enhanced stability of novel liquid compositions
MX2015015518A (es) Metodos y composiciones para el tratamiento del cancer.
MX2016005395A (es) Formulacion estable de insulina glulisina.
EP3878445A3 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
EP3043811A4 (en) Compositions and methods for the delivery of molecules into live cells
EP2978421A4 (en) STABLE NANOCOMPOSITION COMPRISING DOCATEXEL, PROCESS FOR PREPARATION THEREOF, USE THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
MX371349B (es) Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.
PH12015502717A1 (en) Anti-fibrogenic compounds, methods and uses thereof
WO2014104989A8 (en) Pharmaceutical compositions comprising aripiprazole
PH12015502029A1 (en) Phenylephrine resinate particles and use thereof in pharmaceutical formulations
PH12015502015A1 (en) Coated phenylephrine particles and use thereof in pharmaceutical formulations
UY34895A (es) Formulaciones estabilizadas de etanercept
UA103450C2 (ru) Фолат-конъюгированный ферроцен как биологически активное соединение медицинского назначения